ANAB (AnaptysBio) OCF Margin %: -101.42% (As of Mar. 2026)


ANAB AnaptysBio Inc ANAB
67 GF Score
Price $59.29
GF Value $61.87
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is AnaptysBio OCF Margin %?

AnaptysBio ANAB +1.39% 67 OCF Margin % is -101.42% as of Mar. 2026. GuruFocus rates ANAB with a GF Score™ of 67/100 and a GF Value™ of $61.87 (Fairly Valued). The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, AnaptysBio ranks better than 69.79% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. AnaptysBio's Cash Flow from Operations for the three months ended in Mar. 2026 was $-25.9 Mil. AnaptysBio's Revenue for the three months ended in Mar. 2026 was $25.6 Mil. Therefore, AnaptysBio's OCF Margin % for the quarter that ended in Mar. 2026 was -101.42%.

As of today, AnaptysBio's current OCF Yield % is 0.26%.

The historical rank and industry rank for AnaptysBio's OCF Margin % or its related term are showing as below:

ANAB' s OCF Margin % Range Over the Past 10 Years
Min: -970.12   Med: -171.33   Max: 8.4
Current: 1.93

During the past 13 years, the highest OCF Margin % of AnaptysBio was 8.40%. The lowest was -970.12%. And the median was -171.33%.

ANAB's OCF Margin % is ranked better than
69.79% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs ANAB: 1.93

AnaptysBio OCF Margin % Related Terms

AnaptysBio OCF Margin % Historical Data

* Premium members only.

The historical data trend for AnaptysBio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio OCF Margin % Chart

AnaptysBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.69 -715.40 -704.09 -148.27 8.40

AnaptysBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.53 -180.77 -35.84 90.53 -101.42

ANAB vs VIR, GHRS, INVA: OCF Margin % Comparison

For the Biotechnology subindustry, AnaptysBio's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AnaptysBio OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's OCF Margin % distribution charts can be found below:

* The bar in red indicates where AnaptysBio's OCF Margin % falls into.


ANAB
67GF Score
AnaptysBio Inc ANAB
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnaptysBio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

AnaptysBio's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=19.697/234.603
=8.40 %

AnaptysBio's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-25.919/25.556
=-101.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -101.42% mean?
AnaptysBio (ANAB) has a OCF Margin % of -101.42% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AnaptysBio and its competitors. According to the industry distribution chart, AnaptysBio ranks #290 out of 960 companies in the Biotechnology industry, placing it in the top 30.2%.
Is AnaptysBio's OCF Margin % too high?
AnaptysBio's current OCF Margin % is -101.42%. Based on the distribution chart, AnaptysBio ranks #290 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AnaptysBio has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's OCF Margin % compare to VIR and GHRS?
According to the Biotechnology industry distribution chart, AnaptysBio ranks #290 out of 960 companies for OCF Margin %. This puts AnaptysBio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AnaptysBio and its competitors. AnaptysBio's current OCF Margin % is -101.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
Based on GuruFocus' analysis, AnaptysBio (ANAB) is currently considered Fairly Valued. The stock's GF Value™ is $61.87, compared to a current price of $59.29 — trading 4.2% below its estimated fair value. The current OCF Margin % is -101.42%. AnaptysBio's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For AnaptysBio (ANAB), the current OCF Margin % is -101.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued. The current stock price of $59.29 is trading 4.2% below its estimated GF Value™ of $61.87. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for ANAB:

  • OCF Margin %: -101.42%
  • GF Value™: $61.87 vs. price of $59.29 (4.2% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges 0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score

Get the complete analysis for ANAB

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.29
Price
$61.87
GF Value